Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Streamlines Some Pharma Functions, Explores Sales Force “Efficiencies”

This article was originally published in The Tan Sheet

Executive Summary

"Sales force efficiencies" being explored at Johnson & Johnson as one component of a cost-cutting plan will not directly affect the firm's consumer divisions

You may also be interested in...



Big Pharma “Cost Structure” Needs Attention, Lilly CEO Says

The pharmaceutical industry needs to make significant changes to its cost structure to remain competitive over the next three to five years, Lilly CEO Sidney Taurel said

Big Pharma “Cost Structure” Needs Attention, Lilly CEO Says

The pharmaceutical industry needs to make significant changes to its cost structure to remain competitive over the next three to five years, Lilly CEO Sidney Taurel said

Bristol Rethinking Sales Model, May Try New Approach To Sampling

Bristol-Myers Squibb is reexamining the role of sales forces to find new ideas for reaching physicians

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel